Clinical Trials: Unknown Status
Disclaimer: Information regarding clinical trials for NPC disease is obtained from the https://clinicaltrials.gov website and may not capture every trial. Please see links for additional information about specific clinical trials.
Open-Label Study of Long-Term Safety and Efficacy of Intravenous Trappsol Cyclo (HPβCD) in Niemann-Pick Disease Type C
Sponsor
Cyclo Therapeutics, Inc.
Cyclo Therapeutics, Inc.
Information provided by
Cyclo Therapeutics, Inc. (Responsible Party)
Cyclo Therapeutics, Inc. (Responsible Party)
Study Description:
The purpose of this study is to provide continued access to treatment for NPC-1 after participation and completion of the Phase I trial CTD-TCNPC-101, when administered at doses of 1500 mg/kg and 2500 mg/kg by slow IV infusion over a period of 8 to 9 hours every two weeks.
Study of Lithium Carbonate to Treat Niemann-Pick Type C1 Disease
Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Information provided by
Huiwen Zhang, MD, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (Responsible Party)
Huiwen Zhang, MD, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (Responsible Party)
Study Description:
This study is planned to study whether lithium carbonate has protective effect on the brain of Niemann-Pick disease type C1.
More information can be found on https://clinicaltrials.gov
Share This Content